A Phase Ib Multicenter Trial To Determine The Safety, Tolerance And Preliminary Antineoplastic Activity Of Gemcitabine Administered In Combination With Escalating Oral Doses Of OSI-774 To Patient Cohorts With Recently Diagnosed, Gemcitabine-Naive, Advanced Pancreatic Carcinoma Or Other Potentially Responsive Malignancies
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, United States, 85724
Cancer Therapy and Research Center
San Antonio, United States, 78229-3271